Sickle cell disease is the most common inherited blood disorder in America.
Clinical trial findings showed both treatments could reduce pain from vaso-occlusive events, hallmarks of sickle cell disease.
A cutting-edge cure or CRISPR catastrophe? That’s the question facing regulators.
Sickle cell disease is the most common inherited blood disorder in America.
Clinical trial findings showed both treatments could reduce pain from vaso-occlusive events, hallmarks of sickle cell disease.
A cutting-edge cure or CRISPR catastrophe? That’s the question facing regulators.